Topoisomerase II, an essential nuclear enzyme, is a drug target for the treatment of human cancers. Several of the most active antineoplastic agents paralyse this enzyme by stabilising a complex between the enzyme and the DNA strands manipulated by it in the course of its normal function (Wang, 1985; Liu, 1989; Zwelling, 1989) . This stabilised complex poisons the cell by initiating an apoptotic cell death pathway whose biochemistry is not completely understood at present.
Several cell systems that resist the cytotoxic actions of topoisomerase II target drugs have been described. Either the topoisomerase II within the cells resists stabilisation by the drugs as a result of mutations in the coding sequences for the enzyme (Zwelling et al., 1989; Bugg et al., 1991; Lee et al., 1992; Chan et al., 1993; Champain et al., 1994) or the enzyme levels are so low (Takano et al., 1991; Webb et al., 1991; Ritke et al., 1994; Schneider et al., 1994) that the amount of complex formed is insufficient to initiate cell death. Most of these cell systems were developed by repeatedly treating the cell lines and thus are examples of induced drug resistance. By contrast, brain tumours are usually intrinsically resistant to drug therapy, including agents that target topoisomerase II. We acquired a series of human brain tumour cell lines that had not been exposed to cancer chemotherapeutic drugs either in culture or as primary tumours within patients. These tumours are often resistant to commonly used chemotherapeutic agents. Because recent technology allows the transfection of genes (Eder et al., 1993; Liu et al., 1994; Wasserman and Wang, 1994) The cells were then washed and chased with medium for 1 h before their incubation with DMSO or various concentrations of etoposide for 1 h. The cells were lysed and the DNA protein complexes precipitated as previously described (Zwelling et al., 1989) . The rate of topoisomerse TI-mediated DNA relegation was measured using the methods of Hsiang and Liu (1989) .
Alkaline elution assay The tumour cells were radiolabelled by incubation with 0.05 pCi ml-' [2-'4C]thymidine (Amersham) for one doubling time, then chased for the same time period. Mouse leukaemia L1210 cells, used as an internal standard in alkaline elution assays, were radiolabelled with 0.1 pCi ml-' [methyl-3H]thymidine for 16-20 h. Single-strand breaks were quantified using proteinase K in the lysis step, then elution at pH 12.1 at a rate of 0.15 ml min-' for 35 min as previously described by Kohn et al. (1981) . Non-protein concealed breaks were detected without the use of proteinase K at an elution rate of 2 ml h-' for 15 h.
Colony formation assay Expression of the Drosophila topoisomerase II gene was induced by cell exposure to 10 pM dexamethasone for 4-48 h before treatment with medium alone or etoposide (2 h). Cells were then washed twice with phosphate-buffered saline (PBS), re-fed with conditioned media (media removed from subconfluent cells) and incubated for 24 h before trypsinisation and subcloning into fresh media. Colonies were allowed to form for 12 days, then were stained with 0.04% crystal violet in methanol and counted. The results were expressed as survival fraction compared with the colony-forming efficiency of the medium-treated control. from three independent experiments. (1993) . Along with the induction of the transfected gene, the expression of the intrinsic human topoisomerase II (H-topo II) gene unexpectedly decreased (Figure 1) . Examination of the time course of these events revealed that the dexamethasone-induced expression of the D-topo II gene appeared as early as 6 h after dexamethasone addition and persisted for at least 48 h (Figure 2 ). The associated decrease in endogenous H-topo II expression required slightly longer to detect (12 h, Figure 2b and Figure  4a ). The lack of difference between the survival of transfected and non-transfected cells at the high dose of etoposide (50 gM) may simply result from the loss of assay sensitivity at high drug concentrations. Dex treatment did not alter the sensitivity of HBT20-parent or HBT20-MAM cells (Figure 4b and c). Furthermore, the transfection process did not by itself alter etoposide sensitivity since the clonogenic survival of HBT20-parent, HBT20-MAM, and HTB20-dTOP2 without Dex treatment was not statistically different ( Figure 4d ). Careful analysis of this effect at different times following gene induction (dexamethasone treatment) revealed that the 24 h time point was the one at which maximum sensitisation occurred ( Table III ). After that point in time, sensitisation diminished. This was not due to a loss of dexamethasone Table I DNA-protein precipitable comple   chloride responsiveness by the MMTV promoter, as this persisted for at least 72 h ( Figure 5 ). The increased sensitivity of HBT20-dTOP2 Dex-treated cells was limited to etoposide and did not extend to the topoisomerase II-reactive agent amsacrine (Table IV) . This may be because of the relative insensitivity of Drosophila topo II to amsacrine compared with its sensitivity to etoposide (Robinson and Osheroff, 1991 --0--HBT20-dTOP2 Dex(-) MAM without Dex and 31+5 h with Dex; 30+2 h in HBT20-dTOP2 without Dex and 32 + 4 h with Dex (data from three independent experiments). (Figures 1 and 3 ) and sensitisation to 10 giM etoposide increased 3-fold. Thus, the increased sensitivity of the cells correlated with the induction and expression of the D-topo II gene (Table III) (Eder et al., 1993; Liu et al., 1994; Wasserman and Wang, 1994) .
Induction of D-topo II mRNA expression was observed as early as 6 h following stimulation with dexamethasone. This enhanced expression of D-topo II continued for as long as 48 h (Figure 2 ). Enhanced sensitivity to etoposide could be detected after 12 and 24 h, but not at time points greater than 24 h (Table III) . Thus, at a time point when D-topo II was still being expressed (48 h), increased sensitivity to etoposide was lost.
Etoposide targets the enzyme topo II and stabilises the topo 1I-DNA complex. This complex is toxic to the cell. Our hypothesis was that the HBT20-dTOP2 cells were producing more topo II enzyme following dexamethasone stimulation, which resulted in more complex formation after etoposide treatment and increased cell kill. However, more complex formation was not seen in these sensitised transfected cells. This lack of concordance between etoposide-induced cytotoxicity and etoposide-induced DNA cleavage can perhaps be explained by the hypothesis recently proposed by Gerwirtz (1991) . He has proposed that the site rather than the amount of drug-induced, topo II-mediated DNA cleavage dictates the cytotoxicity of any given drug treatment. It is likely that the DNA sites at which the transfected Drosophila enzyme act are not identical to those at which the endogenous human topoisomerase II act (Spitzner and Muller, 1988) . At low concentrations of etoposide, this would mean new DNA sites would be recruited into the cytotoxic process in the Drosophila topoisomerase II transfected cells. Additional sites of drug action could go undetected in alkaline elution assays yet still lead to increased cytotoxicity. The higher etoposide concentration (50 pM) may be sufficiently cytotoxic so that the contribution of this small increase in sites of drug action is of little consequence.
Why then was the increase in sensitivity at the low etoposide concentration lost at 48 h, a time when gene expression was still evident and when the exogenous promoter was still functionally turned on ( Figure 5 )? For our hypothesis of increased cytotoxicity secondary to increased production of the target enzyme topoisomerase II to be operational, the total cellular topo II pool, not just the exogenous portion, must remain elevated. As shown in Figures 2 and 3 , both the expression and the amount of endogenous human topo II protein were down-regulated following induction of the D-topo II gene. Dex treatment had no effect on the endogenous human topoisomerase II mRNA or protein levels in the control transfected HBT20-MAM cells (Figures lb and 3) . therefore. this down-regulation was not merely the result of Dex treatment. The observed decrease in endogenous topo II mRNA was not associated with the accumulation of cells in G1 as the percentage of HBT20-dTOP2 cells in G,, S and G,M was the same as seen with the HBT20-MAM and HBT20-parent cells (Table V) . Dex treatment also did not alter the cell cvcle time or distribution of any of the three cell lines. By 24 h of Dex stimulation, there was significantly less H-topo II protein in the HBT20-dTOP2 cells than in the HBT20-parent. the HBT20-MAM or the HBT2O-dTOP2 unstimulated cells (Figure 3b) 
